Insulin pump treatment of childhood type 1 diabetes

Department of Pediatrics, Yale University, New Haven, Connecticut, United States
Pediatric Clinics of North America (Impact Factor: 2.2). 01/2006; 52(6):1677-88. DOI: 10.1016/j.pcl.2005.07.004
Source: PubMed

ABSTRACT Current goals for the treatment of children and adolescents with type 1 diabetes mellitus include achieving near-normal blood sugar levels, minimizing the risk of hypoglycemia, optimizing quality of life, and preventing or delaying long-term microvascular complications. Continuous subcutaneous insulin infusion (CSII) provides a treatment option that can assist in the attainment of all of these goals in all ages of children. Usage of CSII has been demonstrated to reduce glycosylated hemoglobin levels and frequency of severe hypoglycemia, without sacrifices in safety, quality of life, or weight gain, particularly in conjunction with the use of new insulin analogs and improvements in pump technology. Clinical studies of safety and efficacy of CSII in children are reviewed.

Download full-text


Available from: Amy Steffen, Dec 23, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: "Double diabetes," which refers to the coexistence of type 1 and type 2 diabetes mellitus, is a newly coined term in the diabetic literature. Excessive weight gain and a family history of type 2 diabetes in a patient with type 1 diabetes are the possible major causes. We report a case of double diabetes in a 45-year-old patient with type 1 diabetes mellitus that developed after insulin pump therapy. Insulin pump therapy is a valuable method used in the management of type 1 diabetes mellitus that may provide life comfort. However, this comfort may result in excessive weight gain, which, when combined with a family history of type 2 diabetes mellitus, may predispose to double diabetes. Clinicians must consider this pattern during the use of insulin pump therapy in patients with type 1 diabetes.
    Journal of Diabetes and its Complications 03/2008; 22(2):147-9. DOI:10.1016/j.jdiacomp.2006.10.002 · 1.93 Impact Factor
  • Canadian Journal of Diabetes 04/2013; 37:S153–S162. DOI:10.1016/j.jcjd.2013.01.042 · 0.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: A pilot study was undertaken to determine whether establishment of a Spanish Language Diabetes Clinic (SLDC) for Spanish speaking families conducted by a team of Spanish speaking, Hispanic and non-Hispanic clinicians provides a means to improve control of type 1 diabetes.Methods: The first 21 Hispanic pediatric patients with T1D who enrolled in the SLDC were matched to 21 Hispanic patients treated in the English Language Diabetes Clinic (ELDC) based on age and duration of diabetes. The two groups did not differ significantly with respect to gender, BMI, or A1c. Patients in both groups were followed for 12 months.Results: The mean (±SD) baseline A1c in the SLDC group (8.4±1.0%) was similar to that in the ELDC group (8.6±1.4%, p=0.83). A1c levels fell by 0.5±1.0% (p=0.01) during the year following enrollment in the SLDC but did not change significantly from baseline during the year of follow-up in the ELDC group (decrease of 0.2±0.9%, p=0.1). At the start of the study, only 5 patients (23%) in the SLDC group and only 7 patients (33%) in the ELDC group met the ≤7.5% target A1c level. After one year, 10 of the SLDC patients (48%) compared to only 4 of ELDC patients (19%) had A1C levels ≤7.5% (p=0.01).Conclusions: Our preliminary findings support the hypothesis that overcoming language barriers by the establishment of a SLDC can be an effective means of improving metabolic control in youth with T1D in Hispanic families with limited English language skills.
    Endocrine Practice 06/2013; 19(5):1-19. DOI:10.4158/EP13004.OR · 2.59 Impact Factor